David Nyanjom, MD
Pulmonary Disease · Columbia, MDNPI 1235134370
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,949 of the $197,688 with a category attached, or 65.7%. GSK accounts for 67.5% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2019 at $69,446 and has fallen 68.9% since, to $21,564 in 2025. Among pulmonary disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,193 payments — averaging $165.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$133K
- Mylan Specialty L.p.$28K
- Verona Pharma, Inc.$18K
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Mallinckrodt Hospital Products Inc.$1K
- plus $12K from 42 others
Across 85 payments — averaging $5549.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$171K
- GSK$135K
- AstraZeneca$78K
- Novartis$44K
- Mallinckrodt Enterprises LLC$20K
- Mylan Specialty L.p.$19K
- plus $5K from 3 others
What the payments were for
- Consulting fees$20,96311%
- Speaking & faculty fees$129,94966%
- Travel & lodging$19,56810%
- Food & beverage$26,50613%
- Education$7030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$44,906
- TRELEGY ELLIPTA$41,257
- NUCALA$26,846
- Yupelri$25,910
- Ohtuvayre$17,675
- ANORO$7,320
- ANORO ELLIPTA$2,400
- ACTHAR$211
- XYWAV$132
- Prolastin-C Liquid$113
- TEZSPIRE$110
- BREZTRI$110
- DUPIXENT$110
How this compares
$197,688 in reported general payments places this provider in the 95th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aralast NpAlpha-1-Proteinase Inhibitor | 40 | $396,425 |
| OfevNintedanib Esylate | 29 | $315,100 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 25 | $301,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 249 | $252,258 |
| GlassiaAlpha-1-Proteinase Inhibitor | 15 | $135,806 |
| Dupixent PenDupilumab | 30 | $125,496 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 118 | $96,821 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $70,699 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 82 | $65,499 |
| Spiriva RespimatTiotropium Bromide | 37 | $40,188 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $13,754 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 322 | $10,433 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $8,877 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,206 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $8,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $133,401 | $396,576439 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,308 | $369,04381 claims |
| Grifols USA, LLCProlastin C | $970 | $301,58525 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $676 | $135,80615 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,403 | $105,027143 claims |
| MerckDulera | $61 | $6,92912 claims |
| PfizerEliquis | $146 | $5,96811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 297 pulmonary disease providers in Maryland.
Other pulmonary disease in Columbia
- Edward SchaeferColumbia$13K
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- da Wei LiaoBethesda$310K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.